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 Courbebaisse  et al . 9 compared outcomes 
in patients with 25(OH)D concentration 
less than 30  ng / ml and normal serum cal-
cium, treated or not treated with cholecal-
ciferol. ' ey showed that treating patients 
with 100,000 units of cholecalciferol every 
2 weeks for 2 months may be enough to 
significantly elevate serum levels of 
25(OH)D to above 30  ng / ml and reduce 
PTH levels without consequent hypercal-
cemia or increased urinary calcium excre-
tion, which could adversely a8 ect graG  
function. However, during the less inten-
sive phase of the treatment, when chole-
calciferol was given at the same dose every 
other month, serum levels of 25(OH)D 
decreased again, though they remained 
higher than in control untreated patients 
at 1 year aG er transplantation. ' e message 
to be drawn from this study is that we need 
to prescribe large doses of cholecalciferol 
for our patients aG er renal transplantation. 
In addition, we need similar bold studies 
on the correct dose of cholecalciferol or 
ergocalciferol to prescribe for our patients 
at the di8 erent stages of CKD. 10 
 Current Kidney Disease Outcomes Qual-
ity Initiative guidelines de ne de ciency of 
vitamin D metabolites as less than 15  ng / ml 
for 25(OH)D 3 , but this does not account for 
the other consequences of vitamin D insuf-
ficiency. The first parameter of mineral 
metabolism to be decreased in patients with 
early CKD was shown by Levin  et al. 11  to be 
serum 1,25(OH) 2 D. ' at is an important 
observation, and it would be of great interest 
to test the response of those patients with 
early CKD to oral vitamin D rather than oral 
1,25(OH) 2 D or its analogues. 
 Until then, it is incumbent upon us to 
increase the dose and maintain levels of 
25(OH)D in all our patients and in the gen-
eral population where we may have some 
small inJ uence. We need to rise to the chal-
lenge and make broad public appeals for 
wider supplementation with vitamin D and 
a prudent exposure to sunlight. 
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have no tubular secretion or reabsorp-
tion, and have no extrarenal clearance. In 
order to interpret levels of any proposed 
marker used in estimation of GFR, it is 
important to understand the factors that 
alter the generation, elimination, and 
analysis. ' e factors associated with cre-
atinine are well understood, but this is 
not the case with cystatin C. Cystatin C is 
a 120-amino acid cysteine protease inhib-
itor. It is produced and secreted by all 
nuclear cells. 1 It functions extracellularly 
to inhibit papain-like cysteine protease 
inhibitors. 2 It is freely filtered at the 
glomerulus, reabsorbed by proximal 
tubules via megalin-mediated endocyto-
sis, and catabolized. 3 
 Stevens  et al. 4 (this issue) analyzed 
the associations with cystatin C and 
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 Measuring glomerular filtration rate 
(GFR) in every patient is not practical in 
clinical care or large epidemiologic stud-
ies. ' is leaves us with estimation of GFR 
using endogenous markers, such as cre-
atinine and cystatin C. ' e ideal endog-
enous marker does not exist. An ideal 
marker would have a constant generation 
rate, be freely  ltered at the glomerulus, 
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 Recent studies indicate that serum cystatin C is a better marker of 
glomerular filtration rate (GFR) and is a stronger predictor of cardiovascular 
disease and mortality than serum creatinine. Before cystatin C can gain 
wide acceptance, information about factors that affect generation, 
elimination, and analysis is needed. Stevens  et al. analyze non-GFR – related 
factors associated with cystatin C and creatinine levels. The results will be 
useful in interpreting cystatin C levels in research and clinical practice. 
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creatinine levels in the Chronic Kidney 
Disease Epidemiology Collaboration 
(CKD-EPI), a pooled population of four 
studies with measured GFR. ' eir analy-
sis presents associations before and aG er 
controlling for GFR, associations that 
remained after adjustment indicate 
potential non-GFR – associated factors. 
All four studies involved individuals with 
chronic kidney disease, though the Coop-
erative Study Group population had bet-
ter-preserved GFR values than the other 
three studies. ' e current study is the 
largest to date that has measures of GFR, 
and the authors are uniquely able to ana-
lyze these factors. However, there are 
always issues when multiple studies are 
combined, as there may be di8 erences in 
measurement of covariates. A review of 
their results indicates that there were 
variables with signi cant study interac-
tions. ' is means that the non-GFR asso-
ciations of cystatin C or creatinine varied 
across studies. What is not discussed is 
how these associations varied — were 
there inconsistencies in whether factors 
were associated with cystatin C or creati-
nine aG er controlling for GFR, or was it 
simply the magnitude of the association 
that varied? Consistency across studies 
would support potential causal relation-
ships. 
 Overall, with cystatin C the signi cant 
relationships aG er GFR adjustment were 
relatively small (5 – 10 % ), and some, 
although statistically signi cant, may not 
be clinically relevant, but they do suggest 
possible biological mechanisms for fac-
tors that a8 ect cystatin C values. Most of 
the variables that were associated with 
creatinine and cystatin C, aG er adjust-
ment for GFR, could be broadly catego-
rized as either nutrit ional /  body 
composition (for example, weight, body 
mass index, urine creatinine, phosphate) 
or inJ ammatory (C-reactive protein, log 
white blood cell count). AG er adjustment 
for GFR, but before adjustment for age, 
race, and sex, creatinine had stronger 
non-GFR associations than cystatin C. 
Adjustment for age, race, and sex (sur-
rogates of muscle mass) decreased the 
association of creatinine with these nutri-
tional factors but had less of an e8 ect on 
cystatin C. A potential explanation is that 
cystatin C is less associated with muscle 
mass (lean mass) but is associated with fat 
mass. A number of prior studies have 
found that cystatin C is associated with 
body mass index. 5,6 Knight  et al. , in an 
analysis of the Prevention of Renal and 
Vascular End-Stage Disease (PREVEND) 
study, adjusted for 24-h creatinine clear-
ance and also found an association of 
cystatin C with body mass index and C-
reactive protein. 6 An association of cysta-
tin C with fat mass might also explain the 
association of cystatin C with inJ amma-
tory markers. Adipocytes are active cells 
that secrete a number of peptide hor-
mones involved in insulin resistance, 
inJ ammation, and satiety. 7 Higher body 
mass index, especially if associated with 
abdominal obesity, would be associated 
with higher inJ ammatory marker levels. 
In contradiction to this hypothesis, Taleb 
 et al. found that cathepsins S and K, which 
are inhibited by cystatin C, are upregu-
lated in subcutaneous fat tissue from 
obese individuals, but they did not  nd 
that cystatin C expression was upregu-
lated. 8 Whether there are conditions in 
which cystatin C is upregulated has not 
been well studied. 
 Studies have shown that cystatin C 
is a better predictor of cardiovascular 
disease and mortality than serum creati-
nine – based estimated GFR (eGFR) for-
mulas. 9 Does this relate to more accurate 
classi cation of kidney disease? ' is may 
be the case for populations where there is 
not a large proportion of individuals with 
known kidney disease. Alternatively — the 
better prediction — could it relate to non-
renal factors such as inJ ammation? ' is 
is a question that hopefully the CKD-EPI 
group can answer in the future. 
 There are a number of unanswered 
questions. What clinical role should cysta-
tin C have in the diagnosis of kidney dis-
ease? It is now standard that eGFR is 
reported when creatinine is measured. A 
general weakness of the literature evaluat-
ing eGFR formulas is that there have not 
been studies testing the accuracy of the 
formulas in the general medical popula-
tion who have creatinine measured. Most 
studies are in individuals with known 
kidney disease or at the other extreme, 
healthy transplant donors. Extrapolating 
from these studies to the general popula-
tion can be problematic. 
General population
Cystatin C
CKD
Pcr+
Elderly and women
Cystatin C
CKD
Pcr+
 Figure 1  |  Creatinine vs. cystatin as predictors of CKD. ( a ) Changes in plasma concentration of 
cystatin C predict the risk of renal insufficiency better than plasma creatinine when measured in 
patients with minor changes in GFR in the general population. ( b ) Changes in plasma concentration 
of cystatin C and creatinine when measured together in the elderly and in women may have 
greater predictive value for development of renal insufficiency, as disproportionate increases in 
cystatin C may reflect processes leading to progressive renal disease that cannot be gleaned 
from changes in creatinine alone. CKD, chronic kidney disease; GFR, glomerular filtration rate; 
pcr, plasma creatinine. 
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 There have been concerns about 
the accuracy of the Modification of 
Diet in Renal Disease (MDRD) formula 
in the normal range and in the upper 
range of stage 3 chronic kidney disease 
(CKD). Do all of the individuals diag-
nosed with stage 3 CKD actually have 
CKD? Only some with eGFR in the 60 –
 90  ml / min per 1.73  m 2 range have decre-
ments in GFR and are at risk for 
progression, but it is di3  cult to identify 
these individuals. These cases may 
be a situation in which cystatin C would 
be particularly useful. What is needed is 
a study of measurement of GFR in the 
general population with simultaneous 
measurement of creatinine and cystatin 
C, an area that has not been a high prior-
ity in large epidemiologic studies (Figure 
1a). In addition, we need a study that 
evaluates GFR in the general medical 
population, particularly the elderly, 
where loss of lean mass that affects 
creatinine values may be particularly 
relevant (Figure 1b). 
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 In the general population, a strong asso-
ciation between low bone mineral density 
or osteoporosis and vascular calci cation 
exists. Apparently, demineralization of 
the bone goes along with the formation 
of a bone-like structure in the arteries, 
which is called the calci cation paradox. 
The link between artery calcification 
and bone diseases is also reported in 
patients with chronic kidney disease 
(CKD). Both high- and low-turnover 
bone disease, manifested as hyperpar-
athyroid and adynamic bone, respectively, 
may contribute to the onset and / or pro-
gression of arterial calci cation in renal 
failure patients. High bone formation and 
resorption rates represent an increased 
exchange of calcium and phosphate 
between the serum and the bone com-
partments. The continuous supply of 
these substrates from the bone to the 
serum can be responsible for the close 
association between high bone turnover 
and vascular calci cation. On the other 
hand, in the case of adynamic bone dis-
ease, inactive bone remodeling leads to 
an impaired capacity of the bone to bu8 er 
circulating calcium and phosphate, result-
ing in a decreased rate of incorporation 
of calcium and phosphate into the bone, 
which ultimately augments the risk for 
extraosseous calci cation. 
 In CKD patients, the prevalence of 
osteoporosis is high and bone mineral 
density decreases gradually with declin-
ing renal function. 1 Osteoporosis may 
coexist with either high bone turnover or 
low bone turnover. However, the mecha-
nisms that may explain the concomitant 
appearance of a decreased bone mineral 
density and calci ed areas in the vessel 
wall are still poorly understood. Potential 
mechanisms for this paradox are pre-
sented in  Figure 1 . 
 In CKD patients, inflammatory 
markers such as tumor necrosis factor-  
and interleukin-6 as well as lipids, 
particularly oxidized low-density lipo-
protein, are proposed to be responsible 
for the interaction between bone loss 
and vascular calcification by exerting 
adverse actions in the bone and the vessel 
wall. Oxidized lipids promote osteogenic 
differentiation and mineralization of 
 Prevention of vascular calcification 
with bisphosphonates without 
affecting bone mineralization: 
a new challenge ? 
 Ellen G.  Neven 1 ,  Marc E.  De Broe 1 and  Patrick C.  D ’ Haese 1 
 Arterial calcification has been found to coexist with bone loss. 
Bisphosphonates, used as standard therapy for osteoporosis, inhibit 
experimentally induced vascular calcification, offering perspectives for 
the treatment of vascular calcification in renal failure patients. 
However, Lomashvili  et al .  report that the doses of etidronate and 
pamidronate that are effective in attenuating aortic calcification also 
decrease bone formation and mineralization in uremic rats, limiting 
their therapeutic use as anticalcifying agents.  
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